Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer
January 06, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
January 05, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference
December 14, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 29, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results
November 24, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021
November 17, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease
November 10, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
October 15, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
October 13, 2021 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021
September 27, 2021 09:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...